Patients with localized adenocarcinoma of the prostate classified as T1-2, N0, Nx M0

classified as low or intermediate risk

Patient with PSA \< 15 ng/ml, Gleason score ≤ 7 restricted to the form \[3 + 4\].

Biopsy with at least 12 specimens and a maximum of four out of six invaded sextants

Patient with a pelvic MRI if there is an intermediate risk and a bone scintigraphy if PSA \> 10 ng/ml

Patient affiliated with health insurance or beneficiary of an equivalent plan

Patients 70 years of age or older

Patients with a life expectancy related to age and associated illness estimated to be greater than 5 years

Patients with a life expectancy greater than 10 years and a state of health allowing general anaesthesia.

Patient participating in other biomedical research within 3 months prior to their inclusion in this protocol

Included patient simultaneously participating in another research study

Evaluation of HIFU in TREATMENT OF LOCALIZED PROSTATE CANCER and OF RECURRENCE AFTER RADIOTHERAPY